VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.17 Million in Repligen Corporation $RGEN

Key Points

• Virginia Retirement Systems acquired 8,600 Repligen shares worth approximately $1.17 million during the second quarter. Institutional investors collectively own 97.64% of the company.
• Repligen reported quarterly EPS of $0.54, beating estimates of $0.45, while revenue rose 11.9% year over year to $204.13 million. The company guided to fiscal 2026 EPS of $2.03–$2.09.
• Analysts maintain a generally positive view, with the stock holding an average “Buy” rating and a consensus price target of $168.57. RGEN recently opened at $165.18, while its CFO sold 733 shares valued at $106,285.

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the second quarter, according to its most recent filing with the SEC. The fund acquired 8,600 shares of the biotechnology company's stock, valued at approximately $1,173,000.

Other institutional investors have also added to or reduced their stakes in the company. California State Teachers Retirement System grew its holdings in Repligen by 13,158.5% during the 2nd quarter. California State Teachers Retirement System now owns 8,201,681 shares of the biotechnology company's stock valued at $1,119,037,000 after buying an additional 8,139,821 shares in the last quarter. Angeles Wealth Management LLC increased its position in shares of Repligen by 6.6% during the second quarter. Angeles Wealth Management LLC now owns 2,757 shares of the biotechnology company's stock valued at $376,000 after buying an additional 170 shares during the period. Nykredit A S purchased a new stake in shares of Repligen in the second quarter worth about $269,000. B. Metzler seel. Sohn & Co. AG lifted its holdings in shares of Repligen by 52.8% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 26,361 shares of the biotechnology company's stock worth $3,597,000 after buying an additional 9,108 shares in the last quarter. Finally, Moore Capital Management LP bought a new position in shares of Repligen in the second quarter valued at approximately $5,123,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Activity

In related news, CFO Jason Garland sold 733 shares of the company's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.60% of the company's stock.

Repligen Stock Up 0.3%

RGEN stock opened at $165.18 on Friday. The company's 50 day moving average is $158.22 and its 200 day moving average is $135.29. The stock has a market cap of $9.32 billion, a price-to-earnings ratio of 226.27, a price-to-earnings-growth ratio of 3.01 and a beta of 1.05. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. Repligen's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on RGEN shares. HSBC reduced their price objective on shares of Repligen from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Wednesday, June 3rd. Evercore reissued an "outperform" rating and issued a $160.00 price target on shares of Repligen in a report on Monday, July 6th. Weiss Ratings upgraded shares of Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 13th. Wolfe Research assumed coverage on shares of Repligen in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $145.00 price target on the stock. Finally, Wells Fargo & Company increased their price objective on Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Repligen presently has an average rating of "Buy" and an average price target of $168.57.

About Repligen

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company's portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.